Irinotecan and Cetuximab With or Without Bevacizumab in Treating Patients With RAS Wild-Type Locally Advanced or Metastatic Colorectal Cancer That Cannot Be Removed by Surgery

NCT02292758 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

36

Enrollment

OTHER

Sponsor class

Conditions

Colorectal Adenocarcinoma
RAS Wild Type
Stage IV Colorectal Cancer AJCC v7
Stage IVA Colorectal Cancer AJCC v7
Stage IVB Colorectal Cancer AJCC v7

Interventions

BIOLOGICAL: Bevacizumab
BIOLOGICAL: Cetuximab
DRUG: Irinotecan
OTHER: Laboratory Biomarker Analysis
OTHER: Placebo

Sponsor

Academic and Community Cancer Research United

Collaborators

[object Object]